Evaluate the feasibility of developing a cocaine vaccine using the approach of c

Country:

United States

Notice/Contract Number:

fbo:nihda2008058

Publication Date:

Aug 28, 2008

Deadline:

Jul 28, 2008

Funding Agency:

Department of Health and Human Services

Buyer:

National Institutes of Health

Original Language:

English

Address:

United States

73100000 - Research and experimental development services

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotations are being requested and a written solicitation will not be issued. This acquisition will be processed under Simplified Acquisition Procedures (SAP) and is not a total small business set-aside. The solicitation number is NIHDA2008058 and the solicitation is issued as a request for quotation (RFQ). The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-25. The associated North American Classification System (NAICS) code for this procurement is 5417. The National Institute on Drug Abuse, Intramural Research Program intends to negotiate and award a purchase order to evaluate the feasibility of developing a cocaine vaccine using the approach of conjugating cocaine and/or cocaine derivatives to an adenovirus. The adenovirus may be human or non-human primate; however, NIDA strongly encourages the non-human primate approach because a substantial percentage of humans have pre-exiting anti-human adenovirus immunity, which would limit the effectiveness of a human adenovirus-based cocaine vaccine. If conjugation is successful, the contractor shall utilize the adenovirus and covalently linked small molecule to evaluate the feasibility of generating humoral immunity to cocaine in animals. If necessary, the contractor may devote efforts toward the modification of capsid proteins to enhance interactions with antigen-presenting cells. The contractor shall act independently, and not as an agent of the Government. The contractor shall furnish all necessary labor, materials, supplies, equipment, and services and perform the work set forth. At the end of this effort, the contractor shall provide NIDA with a report that summarizes the specific efforts undertaken, areas of success, and areas of failure. Offers must be submitted no later than 5:00 p.m. Eastern Standard Time on July 28, 2008. For delivery through the postal service, please submit to the Contracting Office Address below. Electronic transmission will be accepted. Contracting Office Address:National Institute on Drug AbuseIntramural Research Program251 Bayview Blvd., Suite 200Baltimore, Maryland 21224 Primary Point of Contact:Carol Lindsay National Institute on Drug Abuse Intramural Research Program 251 Bayview Blvd., Suite 200 Baltimore, MD 21224Telephone: 443-740-2451 Fax: 443-740-2836 Email: clindsay@intra.nida.nih.gov Secondary Point of Contact: Sheila Zichos National Institute on Drug Abuse Intramural Research Program 251 Bayview Blvd., Suite 200Baltimore, MD 21224Telephone: 443-740-2451Fax: 443-740-2836Email: zichoss@intra.nida.nih.gov
Set-aside code: N/A
Place of performance:
21224
Contact: LINDSAY, CAROL A 443-740-2451, clindsay@intra.nida.nih.gov

Link To Document

Email: LINDSAY, CAROL A (clindsay@intra.nida.nih.gov)

Updated on 2008/06/26

Evaluate the feasibility of developing a cocaine vaccine using the approach of c

Request For Proposals

General Information

Contact Information

Goods, Works and Services

Original Text

dgMarket - Tenders and consulting opportunities worldwide